PBM Consolidation: Better Pricing or Just Less Competition?: The growth of specialty pharmaceuticals, including biologics, is forcing payers and employers to look at cost-saving strategies for managing those drugs. How will they do it if only one large PBM rules the specialty pharmacy network?

Biotechnology healthcare Pub Date : 2012-01-01
Ed Silverman
{"title":"PBM Consolidation: Better Pricing or Just Less Competition?: The growth of specialty pharmaceuticals, including biologics, is forcing payers and employers to look at cost-saving strategies for managing those drugs. How will they do it if only one large PBM rules the specialty pharmacy network?","authors":"Ed Silverman","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>While the ramifications of Express Scripts' planned takeover of Medco are being debated, the use of pharmacy benefit managers is being questioned as cost savings decline and transparency issues hang high. And payers and employers still can't get rid of a \"bad taste in the mouth.\" So what does a mega PBM hope to accomplish?</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"9 1","pages":"10-4"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351886/pdf/bh0901010.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology healthcare","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

While the ramifications of Express Scripts' planned takeover of Medco are being debated, the use of pharmacy benefit managers is being questioned as cost savings decline and transparency issues hang high. And payers and employers still can't get rid of a "bad taste in the mouth." So what does a mega PBM hope to accomplish?

PBM整合:更好的定价还是更少的竞争?包括生物制剂在内的特种药品的增长,正迫使支付者和雇主考虑管理这些药品的成本节约策略。如果只有一家大型药品管理公司统治专业药房网络,他们将如何做到这一点?
尽管快捷药方公司计划收购美可的后果仍在争论之中,但由于成本节约下降,透明度问题悬而未决,使用药房福利管理人员也受到质疑。而纳税人和雇主仍然无法摆脱“嘴里的坏味道”。那么,大型PBM公司希望实现什么目标呢?
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信